Nasdaq
$0.9485▼ 9.19%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $11.2MShares out 11.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
32- 5d agoPre-market26.10.20 19:076-KKey event#●●●#●●●
Radiopharm Theranostics Ltd
Radiopharm Theranostics cancelled 3,333,333 listed options held by its directors on October 16, 2026, and issued 140,028,000 new unquoted options under an employee incentive scheme on October 19, 2026. These actions reflect adjustments to director holdings and an expansion of the company's unquoted equity incentive structure.…more
$0.9485-9.19%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15Overnight26.10.15 10:16SCHEDULE 13GOwnership
Radiopharm Theranostics Ltd
Regal Partners Funds Management Pty Ltd has filed a Schedule 13G, reporting a beneficial ownership of more than 5% in Radiopharm Theranostics Ltd. This filing formalizes the investor's stake in the company.…more
$0.9485-9.19%vs prev closeView filingShare - 10.5Pre-market26.10.05 21:006-KKey event
Radiopharm Theranostics Ltd
Radiopharm Theranostics has successfully completed an End-of-Phase 2 meeting with the U.S. FDA regarding RAD101, its radiopharmaceutical imaging agent for brain metastases. The company has secured a clear regulatory framework for its pivotal clinical development plan and has immediately commenced Phase 3 readiness activities.…more
$0.9485-9.19%vs prev closeView filingShare
31 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.5Pre-market26.10.05 21:09#●●●#●●●
Radiopharm Theranostics Completes EOP2 Meeting with FDA for RAD101
Radiopharm Theranostics has successfully concluded its End-of-Phase 2 meeting with the FDA regarding its brain metastasis imaging agent, RAD101. The company is now preparing for Phase 3 clinical development pending the receipt of official meeting minutes.…more
$0.9485-9.19%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.14Pre-market26.09.14 21:00
●●●●●●●● ●●●●● ●●●●●●
Radiopharm Theranostics announced that its RAD101 imaging agent met primary endpoints in a Phase 2b trial, demonstrating 93% concordance with MRI. The company plans to meet with the FDA to align on the protocol for a pivotal Phase 3 trial.…more
$0.9485-9.19%vs prev close - 9.9Pre-market26.09.09 20:00
●●●●●●●● ●●●●● ●●●●●●
Radiopharm Theranostics announced positive safety and tumor-targeting results from its Phase 1 imaging trial of RAD301 in pancreatic ductal adenocarcinoma patients. These findings support the potential for future Phase 2 development, though the drug remains in early-stage clinical testing.…more
$0.9485-9.19%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report